At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 246 enrolled
Drug / intervention
MMH-MAP +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries
In Brief
A Phase 3 clinical trial evaluating MMH-MAP and Placebo for Cognitive Disorders. Completed, enrolled 246 participants across 22 sites.
Detailed Summary
The clinical trial to valuate efficacy and safety of MMH-MAP in the treatment of cognitive disorders in patients with ischemic stroke in the carotid arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Disorders
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedMar 2020
Primary CompletionFeb 2023
TodayJul 2026
First PostedMar 4, 2020
Enrollment StartDec 12, 2019
Primary CompletionFeb 7, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 6.3 years ago
Interventions
MMH-MAPdrug
Oral administration
Placebodrug
Oral administration